Stable Cell Line Development
Type: Forecast
Overview
Description
The ongoing work is to validate the method, which will require larger quantities of purified mAb-G and mAb-NG. Due to the low production yield of mAb-G and mAb-NG from available mouse hybridomas, 3 stable cell lines expressing recombinant mAb-G and mAb-NG - full-length form for mAb-G only, and both full-length and single-chain forms for mAb-NG - are needed.
Est. Value
Min: $25,000
Max: $250,000
Max: $250,000
Est. Award Date
27-Jan
Future Opp
Source Est. Solicitation Date
26-Nov
Set Aside
To be determined
Place of Performance
USA
Forecast Source
Department of Health and Human Services
Center for Drug Evaluation and Research is forecasted to issue a procurement for Stable Cell Line Development around 27-Jan worth up to $250,000.
Agency
Source Level 1 Agency
Department of Health and Human Services
Source Level 2 Agency
FDA
Source Level 3 Agency
CDER
Contacts
Potential Bidders and Partners
Similar Active Opportunities
Additional Detail
Date Published
11/6/26
Date Modified
11/7/26
Additional Notes
Program Office: 75F401; Contracting Office: 75F402